Please ensure Javascript is enabled for purposes of website accessibility

Why TG Therapeutics Is Tumbling 15% Today

By Todd Campbell - Updated Oct 16, 2017 at 2:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

FDA approval for its lead drug candidate may have just become a bit more uncertain.

What happened

After TG Therapeutics, Inc.'s(TGTX -1.62%) discussion with the FDA regarding its most advanced clinical-stage drug raised concerns over a speedy approval, shares in the company are losing 15% of their value as of 2 pm EDT.

So what

TG Therapeutics reported earlier this year that adding its TG-1101, or ublituximab, to AbbVie Inc.'s (ABBV -0.64%) and Johnson & Johnson's (JNJ 0.29%) top-selling Imbruvica resulted in an objective response rate (ORR) of 78% in patients with high-risk chronic lymphocytic leukemia. The complete response rate to the two-drug combination was 7%. These results matched up favorably to the 45% ORR and 0% complete response rates for Imbruvica on its own.

A man looking at a computer with smoke coming out of his ears.


The FDA has been suggesting that it's open to using surrogate endpoints like ORR rather than overall survival when considering new cancer drugs for approval, and the combination of ublituximab's solid data and a willing FDA has led investors to believe ublituximab could win an accelerated OK.

Today, management poured a little cold water on that thinking.

After TG Therapeutics discussed ublituximab with the regulator, the use of ORR as an endpoint for approval remains up in the air. Instead, it seems the FDA might prefer progression-free survival data. TG Therapeutics expects to have a follow-up conversation to discuss this in more depth with the FDA before the end of 2017.

Now what

There's a big need for new therapies that can help CLL patients, but ublituximab's approval timeline just became a bit fuzzy. The company's current thinking is that it will file for FDA approval in the second quarter of 2018. If the FDA cooperates and TG Therapeutics hits that filing goal, then ublituximab could make its way to market either late next year or early in 2019, depending on the FDA's review time.

Overall, TG Therapeutics' ublituximab appears to be effective, and while anything can happen, I think this drug has a good shot at making it across the finish line. If I'm right, then it could enjoy peak sales in the nine figures someday. The company's got other ongoing trials that could have data available soon, too, and that could ultimately allow it to address an even bigger opportunity. Given the upcoming catalysts, buying this company's shares on a pull-back could be a good bet.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

TG Therapeutics Stock Quote
TG Therapeutics
$4.25 (-1.62%) $0.07
Johnson & Johnson Stock Quote
Johnson & Johnson
$177.51 (0.29%) $0.52
AbbVie Inc. Stock Quote
AbbVie Inc.
$153.16 (-0.64%) $0.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.